keyword
MENU ▼
Read by QxMD icon Read
search

MCDA

keyword
https://www.readbyqxmd.com/read/28303777/placental-up-regulation-of-leptin-and-arms2-is-associated-with-growth-discordance-in-monochorionic-diamniotic-twin-pregnancies
#1
Luming Sun, Jia Zhou, Kai Wang, Jian Wang, Ling Shang, Jianguang Zhang, Junqing Wu, David S Cram
Fetal growth discordance is a relatively common complication of monochorionic diamniotic (MCDA) twin pregnancies and is caused by a combination of maternal and placental factors. The aim of the study was to survey placental gene expression patterns and identify genes associated with growth discordance. Clinical samples comprised eight growth-discordant MCDA twin placentas (31+3-34+4 weeks gestational age) and six growth-concordant twin placentas (31+2-37 weeks gestational age). Gene expression libraries were constructed from placental biopsy samples and analyzed by RNA-sequencing...
April 2017: Twin Research and Human Genetics: the Official Journal of the International Society for Twin Studies
https://www.readbyqxmd.com/read/28292498/treacle-and-smallpox-two-tests-for-multicriteria-decision-analysis-models-in-health-technology-assessment
#2
Alec Morton
Multicriteria decision analysis (MCDA) is rightly receiving increasing attention in health technology assessment. Nevertheless, a distinguishing feature of the health domain is that technologies must actually improve health, and good performance on other criteria cannot compensate for failure to do so. We argue for two reasonable tests for MCDA models: the treacle test (can a winning intervention be incompletely ineffective?) and the smallpox test (can a winning intervention be for a disease that no one suffers from?)...
March 2017: Value in Health: the Journal of the International Society for Pharmacoeconomics and Outcomes Research
https://www.readbyqxmd.com/read/28212954/evaluation-of-copd-treatments-a-multicriteria-decision-analysis-of-aclidinium-and-tiotropium-in-the-united-states
#3
Kevin Marsh, Erica Zaiser, Panagiotis Orfanos, Suzanne Salverda, Teresa Wilcox, Shawn Sun, Shailja Dixit
BACKGROUND: Comparisons of the use of aclidinium bromide and tiotropium bromide for the treatment of chronic obstructive pulmonary disease often concentrate on key end points (exacerbations) at the expense of other benefits and risks. Multicriteria decision analysis (MCDA) can help overcome this by using stakeholder preferences to combine multiple end points into an overall value estimate. OBJECTIVES: To evaluate the use of aclidinium bromide twice daily via Pressair™ (AstraZeneca Pharmaceuticals LP, Wilmington, DE) and of tiotropium once daily via HandiHaler(®) (Boehringer Ingelheim Pharmaceuticals, Inc...
January 2017: Value in Health: the Journal of the International Society for Pharmacoeconomics and Outcomes Research
https://www.readbyqxmd.com/read/28203120/international-lessons-in-new-methods-for-grading-and-integrating-cost-effectiveness-evidence-into-clinical-practice-guidelines
#4
REVIEW
Kathryn M Antioch, Michael F Drummond, Louis W Niessen, Hindrik Vondeling
Economic evidence is influential in health technology assessment world-wide. Clinical Practice Guidelines (CPG) can enable economists to include economic information on health care provision. Application of economic evidence in CPGs, and its integration into clinical practice and national decision making is hampered by objections from professions, paucity of economic evidence or lack of policy commitment. The use of state-of-art economic methodologies will improve this. Economic evidence can be graded by 'checklists' to establish the best evidence for decision making given methodological rigor...
2017: Cost Effectiveness and Resource Allocation: C/E
https://www.readbyqxmd.com/read/28187230/a-simple-way-to-unify-multicriteria-decision-analysis-mcda-and-stochastic-multicriteria-acceptability-analysis-smaa-using-a-dirichlet-distribution-in-benefit-risk-assessment
#5
Gaelle Saint-Hilary, Stephanie Cadour, Veronique Robert, Mauro Gasparini
Quantitative methodologies have been proposed to support decision making in drug development and monitoring. In particular, multicriteria decision analysis (MCDA) and stochastic multicriteria acceptability analysis (SMAA) are useful tools to assess the benefit-risk ratio of medicines according to the performances of the treatments on several criteria, accounting for the preferences of the decision makers regarding the relative importance of these criteria. However, even in its probabilistic form, MCDA requires the exact elicitations of the weights of the criteria by the decision makers, which may be difficult to achieve in practice...
February 10, 2017: Biometrical Journal. Biometrische Zeitschrift
https://www.readbyqxmd.com/read/28159477/assessment-of-skin-sensitization-under-reach-a-case-report-on-vehicle-choice-in-the-llna-and-its-crucial-role-preventing-false-positive-results
#6
Nico Watzek, Franz Berger, Susanne Noreen Kolle, Tanja Kaufmann, Matthias Becker, Bennard van Ravenzwaay
In the EU, chemicals with a production or import volume in quantities of one metric ton per year or more have to be tested for skin sensitizing properties under the REACH regulation. The murine Local Lymph Node Assay (LLNA) and its modifications are widely used to fulfil the data requirement, as it is currently considered the first-choice method for in vivo testing to cover this endpoint. This manuscript describes a case study highlighting the importance of understanding the chemistry of the test material during testing for 'skin sensitization' of MCDA (mixture of 2,4- and 2,6-diamino-methylcyclohexane) with particular focus on the vehicle used...
January 31, 2017: Regulatory Toxicology and Pharmacology: RTP
https://www.readbyqxmd.com/read/28153653/prenatal-diagnosis-and-management-of-vasa-previa-in-twin-pregnancies-a%C3%A2-case-series-and%C3%A2-systematic-review
#7
REVIEW
Eric Jauniaux, Yaakov Melcer, Ron Maymon
BACKGROUND: Twin pregnancies are at higher risks of velamentous cord insertion and vasa previa. In vitro fertilization is an additional risk factor of abnormal cord insertion and thus the incidence of vasa previa is likely to increase over the next decades. OBJECTIVE: We sought to evaluate the role of ultrasound imaging in optimizing the management of twins diagnosed with vasa previa antenatally. STUDY DESIGN: We searched our database for twin pregnancies diagnosed with vasa previa and managed antenatally using measurements of cervical length and performed a systematic review of articles that correlated prenatal diagnosis of vasa previa in twins and pregnancy outcome...
January 30, 2017: American Journal of Obstetrics and Gynecology
https://www.readbyqxmd.com/read/28138243/development-of-multiple-cross-displacement-amplification-label-based-gold-nanoparticles-lateral-flow-biosensor-for-detection-of-listeria-monocytogenes
#8
Yi Wang, Hui Li, Yan Wang, Hua Li, Lijuan Luo, Jianguo Xu, Changyun Ye
Listeria monocytogenes, one of most problematic foodborne pathogens, is responsible for listeriosis in both humans and animals and mainly transmitted through the food chain. In this report, we propose a simple, rapid, and nearly instrument-free molecular technique using multiple cross displacement amplification (MCDA) label-based gold nanoparticles lateral flow biosensor (LFB) for specific, sensitive, and visual detection of L. monocytogenes. The MCDA-LFB method was carried out at a constant temperature (61°C) for only 20 min during the reaction stage, and then the amplification mixtures were directly detected by using LFB, eliminating the use of an electrophoresis instrument, special reagents, or amplicon analysis equipment...
2017: International Journal of Nanomedicine
https://www.readbyqxmd.com/read/28095876/multi-criteria-decision-analysis-mcda-testing-a-proposed-mcda-framework-for-orphan-drugs
#9
C Schey, P F M Krabbe, M J Postma, M P Connolly
BACKGROUND: Since the introduction of the orphan drugs legislation in Europe, it has been suggested that the general method of assessing drugs for reimbursement is not necessarily suitable for orphan drugs. The National Institute for Health and Clinical Excellence indicated that several criteria other than cost and efficacy could be considered in reimbursement decisions for orphan drugs. This study sought to explore the multi-criteria decision analysis (MCDA) framework proposed by (Orphanet J Rare Dis 7:74, 2012) to a range of orphan drugs, with a view to comparing the aggregate scores to the average annual cost per patient for each product, and thus establishing the merit of MCDA as a tool for assessing the value of orphan drugs in relation to their pricings...
January 17, 2017: Orphanet Journal of Rare Diseases
https://www.readbyqxmd.com/read/28019130/eliciting-societal-preferences-of-reimbursement-decision-criteria-for-anti-cancer-drugs-in-south-korea
#10
Sun-Hong Kwon, Sun-Kyeong Park, Ji-Hye Byun, Eui-Kyung Lee
INTRODUCTION: In order to look beyond the cost-effectiveness analysis, this study used a multi-criteria decision analysis (MCDA), which reflects societal values with regard to reimbursement decisions. This study aims to elicit societal preferences of the reimbursement decision criteria for anti cancer drugs from public and healthcare professionals. METHODS: Eight criteria were defined based on a literature review and focus group sessions: disease severity, disease population size, pediatrics targets, unmet needs, innovation, clinical benefits, cost-effectiveness, and budget impacts...
January 3, 2017: Expert Review of Pharmacoeconomics & Outcomes Research
https://www.readbyqxmd.com/read/28012386/performance-evaluation-of-restaurant-food-waste-and-biowaste-to-biogas-pilot-projects-in-china-and-implications-for-national-policy
#11
Djavan De Clercq, Zongguo Wen, Fei Fan
The objective of this research was to conduct a performance evaluation of three food waste/biowaste-to-biogas pilot projects across 7 scenarios in China based on multi-criteria decision analysis (MCDA) methodology. The projects ranked included a food waste-biogas project in Beijing, a food waste-biogas project in Suzhou and a co-digestion project producing biomethane in Hainan. The projects were ranked from best to worst based on technical, economic and environmental criteria under the MCDA framework. The results demonstrated that some projects are encountering operational problems...
March 15, 2017: Journal of Environmental Management
https://www.readbyqxmd.com/read/27976822/multi-criteria-decision-analysis-applied-to-harmful-algal-bloom-management-a-case-study
#12
Chengfang Pang, Artur Radomyski, Vrishali Subramanian, Mandana Nadimi-Goki, Antonio Marcomini, Igor Linkov
Harmful Algal Blooms (HABs) have received greater attention in recent years due to an increase in the frequency of outbreaks and a growing potential for blooms to exact considerable economic losses and negatively impact ecosystem health. Human activity has been shown to intensify HAB outbreaks through increased eutrophication, elevated local air and water temperatures, disturbance of the thermal stratification of lakes, and modification of local hydrology. With the advent of new remediation technologies and a better understanding of the ecological factors affecting HABs, mitigating the adverse effects of HABs has become more feasible than ever before, but still requires balancing mitigation efficiency, environmental impacts, costs, and stakeholder needs...
December 15, 2016: Integrated Environmental Assessment and Management
https://www.readbyqxmd.com/read/27972736/application-of-multi-criteria-decision-analysis-mcda-scoring-as-an-hta-methodology-for-off-patent-pharmaceuticals-opp-in-emerging-markets
#13
D Brixner, N Maniadakis, Z Kaló, S Hu, A Johnston, J Shen, K E Wijaya
No abstract text is available yet for this article.
November 2016: Value in Health: the Journal of the International Society for Pharmacoeconomics and Outcomes Research
https://www.readbyqxmd.com/read/27971200/multi-criteria-decision-analysis-mcda-common-tools-for-different-needs-supporting-healthcare-decision-making-in-spain
#14
A Gilabert-Perramon, C Lens, J I Betolaza, J C March, J Espín, S Merino-Montero, A Gil, X Badia
No abstract text is available yet for this article.
November 2016: Value in Health: the Journal of the International Society for Pharmacoeconomics and Outcomes Research
https://www.readbyqxmd.com/read/27971101/mcda-application-in-central-and-eastern-europe-selection-of-the-most-important-criteria-based-on-examples
#15
B Nemeth, O Piniazhko
No abstract text is available yet for this article.
November 2016: Value in Health: the Journal of the International Society for Pharmacoeconomics and Outcomes Research
https://www.readbyqxmd.com/read/27971090/the-value-of-mcda-in-health-technology-assessment-a-explorative-study-in-the-dutch-context
#16
J A van Til, C G Groothuis-Oudshoorn, R Baltussen, J Zwaap, B Boer, M J IJzerman
No abstract text is available yet for this article.
November 2016: Value in Health: the Journal of the International Society for Pharmacoeconomics and Outcomes Research
https://www.readbyqxmd.com/read/27970692/multi-criteria-decision-analysis-from-the-cost-effectiveness-perspective-is-mcda-a-coherent-way-to-allocate-healthcare-resources
#17
J F O'Mahony
No abstract text is available yet for this article.
November 2016: Value in Health: the Journal of the International Society for Pharmacoeconomics and Outcomes Research
https://www.readbyqxmd.com/read/27970527/eliciting-payers-preferences-in-central-and-eastern-europe-results-of-mcda-case-study
#18
O Piniazhko, O Zalis'ka, V Zah
No abstract text is available yet for this article.
November 2016: Value in Health: the Journal of the International Society for Pharmacoeconomics and Outcomes Research
https://www.readbyqxmd.com/read/27970454/ht5-development-of-a-multi-criteria-decision-analysis-mcda-framework-for-health-care-decision-making-in-catalonia-spain-pilot-study-focused-in-orphan-drugs
#19
A Gilabert-Perramon, J Torrent-Farnell, A Catalan, A Prat, M Fontanet, R Puig-Peiró, S Merino-Montero, H Khoury, M M Goetghebeur, X Badia
No abstract text is available yet for this article.
November 2016: Value in Health: the Journal of the International Society for Pharmacoeconomics and Outcomes Research
https://www.readbyqxmd.com/read/27928659/amplifying-each-patient-s-voice-a-systematic-review-of-multi-criteria-decision-analyses-involving-patients
#20
REVIEW
Kevin Marsh, J Jaime Caro, Alaa Hamed, Erica Zaiser
BACKGROUND: Qualitative methods tend to be used to incorporate patient preferences into healthcare decision making. However, for patient preferences to be given adequate consideration by decision makers they need to be quantified. Multi-criteria decision analysis (MCDA) is one way to quantify and capture the patient voice. The objective of this review was to report on existing MCDAs involving patients to support the future use of MCDA to capture the patient voice. METHODS: MEDLINE and EMBASE were searched in June 2014 for English-language papers with no date restriction...
December 7, 2016: Applied Health Economics and Health Policy
keyword
keyword
61220
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"